Kaligia Biosciences receives EU approval for its RBA-2 device for rapid COVID-19 screening
Kaligia Biosciences’ Rapid Biofluid Analyzer 2 has received a CE mark and is ready for the European market.
We are awaiting approval by the FDA in US and by DHSC in UK.
Kaligia Biosciences
On the forefront of healthcare technology
Revolutionary non-invasive point of care devices.
Our Basic Process
Quantifiable Results, Unprecedented Speed.
Kaligia Biosciences is tapping into the power of emerging technologies and creative problem solving to innovate a new breed of sensing devices. These devices, which produce quantifiable results with unprecedented speed and accuracy, align with Kaligia Bieosciences’s mission to redefine medical diagnosis and transform healthcare delivery from reactive to proactive.
Collection
Sample fluid collected from patient.
Spectroscopy
High-intensity laser and detector records unique light signatures.
Machine Learning
Proprietary algorithms analyze the light signatures.
Rapid Results
Results delivered almost instantaneously.
Medical Partnerships
Solving Complex Problems Together
Kaligia Bioscience has begun clinical trials in partnership with numerous hospitals in the Tampa Bay area.
